Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Lam Research Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Lam Research Corporation trades at $335 (market cap $438.11B). The key difference: Lam Research Corporation is far larger — about 11× Alnylam Pharmaceuticals, Inc.'s market cap, and Lam Research Corporation pays a 0.3% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LRCX | |
|---|---|---|
Market Cap | $39.89B | $438.11B |
Sector | Health | Technology |
52-Week High | $491.22 | $433.33 |
52-Week Low | $278.09 | $94.84 |
Enterprise Value | $38.15B | $437.10B |
Dividend Yield | — | 0.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Lam Research (LRCX) trades at $350.33, down 0.8% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with revenue growth to $18.44B in 2025 and net income of $5.36B, supported by consistent earnings beats. Recent news highlights AI-driven demand for semiconductor equipment, though valuation ratios like a P/E of 66.22 raise concerns about premium pricing.
Outlook remains positive with a consensus price target of $393, representing 12% upside, driven by AI infrastructure spending. Risks include high valuation sensitivity and semiconductor cycle volatility. Analyst sentiment is strongly bullish with 78% buy ratings, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
